Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
104
datasets available to search
ShareScore release 0.9.0
Dataset results
104 results for “ESO”
Decoding NY-ESO-1 TCR T Cells: Transcriptomic Insights Reveal Dual Mechanisms of Tumor Targeting in a Melanoma Murine Xenograft Model
<p><span>Single-cell RNA-seq data of NY-ESO-1-specific TCR T-cells generated with the BD Rhapsody™ system.</span></p> <p><span>Biogroup information: Control (<em>n</em><span> </span>= 4), PB (murine peripheral blood, <em>n</em><span> </span>= 4).</span></p> <p><span>Cell preparation: NY-ESO-1-specific TCR T-cells were obtained via a retroviral transduction of an anti-NY-ESO-1-TCR construct, murine peripheral blood T-cells were enriched using anti-CD3 magnetic separation via MojoSortTM Human CD3 Selection Kit.</span></p> <p><span>Single-cell analysis system: BD Rhapsody™</span></p> <p><span>Library strategy: 3' mRNA sequencing</span></p> <p><span>Library preparation protocol: BD Rhapsody™ Targeted mRNA and Sample Tag Library Preparation</span></p> <p><span>mRNA panel: BD Rhapsody™ Immune Response Panel HS</span></p> <p><span>BD Pipeline version: 1.11L</span></p>
Complementary figures for paper 'The ESO UVES/FEROS Large Programs of TESS OB pulsators II. On the physical origin of macroturbulence'
<p>These are figures from Appendices C and D of the paper <strong>'The ESO UVES/FEROS Large Programs of TESS OB pulsators II. On the physical origin of macroturbulence' (Serebriakova et al. Accepted on 17 Oct 2024 for publication in A&A)</strong>. Appendices C and D are moved to Zenodo following the request of the editor. The figures demonstrate MESA model properties used to compare with observed macroturbulent velocities in massive stars. Appendix C focuses on emphasising the role of opacity bumps and subsurface convection throughout evolution. Appendix D explores wave propagation in these models.</p> <p><strong>Appendix C: MESA internal profiles</strong>. Each figure contains a grid of model internal profiles of stellar properties computed with MESA. Initial mass varies in rows: 60, 20, 12, 7, and 3 Solar masses. In columns, three evolutionary stages are presented: MS, TAMS, and Hertzsprung gap. Models in Fig.1-4 were computed with Solar metallicity Z=0.014, and in Fig. 5-8 - with LMC metallicity Z=0.006. Fig. 1,5 - opacity and convective velocity VS temperature, Fig. 2,6 - opacity and convective velocity VS radius(zoomed), Fig. 3,7 - opacity and convective velocity VS radius(full), Fig. 4,8 - Sign of squared Brunt-Väisälä frequency and convective velocity as a fraction of sound speed VS radius. See the paper for details. </p> <p><strong>Appendix D: Propagation diagrams</strong>. Each figure contains a grid of propagation diagrams (shaded with g-modes and p-modes cavities) computed for the same models as before. Fig. 3 and 6 are complemented with tunnelling frequency omega_min - see 'Section 5: On wave tunnelling through subsurface convective layers' for details with examples in Fig. 8 of the paper. </p> <p> </p>
La Silla (ESO) Atmospheric Extinctions
Open the record for dataset details and reuse information.
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
ClinicalTrials.gov study NCT01967823. IPD Sharing: NO. Countries: 1. Publications: 3.
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
ClinicalTrials.gov study NCT01343043. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
ClinicalTrials.gov study NCT00670748. IPD Sharing: NO. Countries: 1. Publications: 4.
Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma
ClinicalTrials.gov study NCT00518206. IPD Sharing: YES. Countries: 1. Publications: 2.
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
ClinicalTrials.gov study NCT00623831. IPD Sharing: YES. Countries: 1. Publications: 1.
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
ClinicalTrials.gov study NCT02062359. IPD Sharing: NO. Countries: 1. Publications: 3.
NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors
ClinicalTrials.gov study NCT00299728. IPD Sharing: NO. Countries: 1. Publications: 2.
Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer
ClinicalTrials.gov study NCT00292045. IPD Sharing: NO. Countries: 2. Publications: 2.
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
ClinicalTrials.gov study NCT03168438. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Eso
ClinicalTrials.gov study NCT04467515. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers
ClinicalTrials.gov study NCT03515551. IPD Sharing: NO. Countries: 3. Publications: 1.
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
ClinicalTrials.gov study NCT00142454. IPD Sharing: NO. Countries: 1. Publications: 1.
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ClinicalTrials.gov study NCT00616941. IPD Sharing: YES. Countries: 1. Publications: 2.
Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma
ClinicalTrials.gov study NCT02992743. IPD Sharing: YES. Countries: 1. Publications: 1.
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
ClinicalTrials.gov study NCT00199849. IPD Sharing: NO. Countries: 1. Publications: 1.
A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.
ClinicalTrials.gov study NCT00199836. IPD Sharing: NO. Countries: 1. Publications: 2.
The VISTA Variables in the Vía Láctea eXtended (VVVX) ESO public survey: Completion of the observations and legacy - Appendix A
<p><strong>Table A.1. </strong>List the VVV+VVVX tiles and observed number of epochs. We present the tile names and centre coordinates in Equatorial and Galactic systems (see Fig. A.1 at the end for the spatial distribution). Columns 6 to 8 present the number of epochs observed in J, H and Ks during the VVV and VVVX campaigns. The first number is the total of epochs, and in parentheses the number of epochs observed in VVV and VVVX, respectively.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.